Vol 6, Supplement 3 (May 2017): Translational Cancer Research

Editorial

Targeted therapy in small cell lung cancer: can DLL3 notch up a victory?
Jonathan M. Lehman, Leora Horn
Concomitant ALK/KRAS and ALK/EGFR mutations in non small cell lung cancer: different profile of response to target therapies
Federica Zito Marino, Andrea Ronchi, Marina Accardo, Renato Franco
Cognitive complaints in breast cancer patients treated with chemotherapy: a reality?
Marie Lange, Florence Joly
RIPK1-TRAF2 interplay on the TNF/NF-κB signaling, cell death, and cancer development in the liver
Satomi Yamamoto, Tomoo Iwakuma
New players in the Bruton’s tyrosine kinase vs. ibrutinib match
Stefania Fiorcari, Rossana Maffei, Roberto Marasca
Increased lipid desaturation and ovarian cancer stem cells
Thomas W. Grunt, Peter Valent
Long-term impact of staging breast magnetic resonance imaging—a risk for overtreatment?
Anne M. Kuritzky, Marie Catherine Lee
Portal vein tumor thrombus should not be considered as a contraindication for liver resection
Cheng-Qian Zhong, Xiu-Ping Zhang, Shu-Qun Cheng
Eastern experience: surgical resection may be the first choice of treatment for selected hepatocellular carcinoma patients with portal vein tumor thrombus
Xiu-Ping Zhang, Cheng-Qian Zhong, Shu-Qun Cheng
Vascular-targeted photodynamic therapy: a glimpse in the future of Urology?
Panagiotis Kallidonis, Evangelos N. Liatsikos
METLung: a disappointing result in a challenging patient population
Jeffrey Zweig, Heather Wakelee
Osimertinib for EGFR T790M positive non-small cell lung cancer—making it happen, turning good idea into great results
Tao Tao, Chunxia Su, Shengxiang Ren, Caicun Zhou
Characterizing advanced or metastatic adenocarcinoma of lung— one step closer?
Ka Man Cheung, James Chung Hang Chow, William Chi Shing Cho
Targeting Bruton’s tyrosine kinase expression levels through microRNAs in chronic lymphocytic leukemia treatment
Simar Pal Singh, Jasper Rip, Rudi W. Hendriks
Gefitinib in combination with pemetrexed in patients with advanced non-small cell lung cancer harboring EGFR mutations: is there any difference in acquired resistance mechanism between gefitinib monotherapy and the combination treatment?
Tatsuya Yoshida, Toyoaki Hida
Bacteriogenic magnetic nanoparticles as magnetic resonance imaging contrast agents
Dawen Zhao
What can we learn from 3 phase III trials of ASCEND-4: ceritinib vs. platinum/pemetrexed with pemetrexed maintenance, PROFILE 1004: crizotinib vs. platinum/pemetrexed, and J-ALEX: alectinib vs. crizotinib?
Nobuaki Ochi, Nagio Takigawa
Cancer therapy by targeting the Warburg effect with miR-143 and response monitoring with 18F-FDG PET
Kyung-Ho Jung, Kyung-Han Lee
Targeting angiogenesis in small cell lung cancer
Gerhard Hamilton, Barbara Rath
The pathogenesis of follicular lymphoma, beyond apoptosis resistance
Marcelo A. Navarrete, Pablo Oppezzo
Upfront radiation versus EGFR-TKI: which is the best approach for EGFR-mutated NSCLC patients with brain metastasis?
Francesco Passiglia, Christian Rolfo
Bevacizumab in extensive-disease small cell lung cancer: the search continues
Avyakta Kallam, Apar Kishor Ganti
Angiogenesis inhibitors for small cell lung cancer
Sang-Yun Song, Cheol-Kyu Park, In-Jae Oh, Young-Chul Kim
The success of NRG-GBM-RPA: biomarker-based classification, where to next?
Cheng-Chia Wu, Deborah R. Smith, Christine Chin, Tony J. C. Wang
Transarterial chemoembolization (TACE) combined with Sorafenib is more effective than TACE for hepatocellular carcinoma with portal vein tumor thrombus
Ze-Han Zhang, Hui-Min Zhu, Teng-Fei Zhou, Nan Li
Is it time to consider the sentinel lymph node mapping the new standard in endometrial cancer?
Andrea Papadia, Maria Luisa Gasparri, Michael D. Mueller
Harmonization of programmed cell death ligand-1 diagnostic assays in non-small cell lung cancer
Amy Popple, Timothy M. Illidge
Promising results from Checkmate 012: better patients or better immunotherapy?
Jaime Hunt, Maria A. Velez, Krikor Bornazyan, John Madrigal, James Carroll, Edward B. Garon
Improving the safety of associating liver partition and portal vein ligation for staged hepatectomy
Pål-Dag Line, Bjørn Atle Bjørnbeth
Aneuploidy meets network analysis: leveraging copy number alterations to identify molecular pathways disrupted in high-grade serous ovarian carcinomas
Yuchae Jung, Tae-Min Kim
RIPK1 and allies in the battle against hepatocyte apoptosis and liver cancer
Vangelis Kondylis
Branched chain amino acid metabolism and cancer: the importance of keeping things in context
Elizabeth M. Selwan, Aimee L. Edinger
Targeting cancer with tumor-specific therapeutic strategies—metabolic reprogramming beyond the Warburg effect
Paul Grippo, Ajay V. Maker
Commentary on “The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion”
Lori M. Minassian, Daniel Sanwalka, Charles H. Graham
Haploinsufficiency and mutation are two sides of the cancer coin as cause and therapeutics target
Qianqian Song, Wei Zhang, Yan Sun
Getting to know ovarian cancer spheroid: opportunity for spheroid-targeted therapy
Yuying Zhang, Lingli Long, Tiefeng Cao, Wang Min
Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
Nobuhisa Akamatsu, Junichi Togashi, Kiyoshi Hasegawa, Norihiro Kokudo
STAT3: a crucial target for ovarian cancer stem cells that inhibits WNT signaling through a novel epigenetic mechanism
Mijung Kwon, Steven K. Libutti
Complement and disease: better no factor H than bad factor H
Paul N. Barlow
Osimertinib a new weapon in epidermal growth factor receptor-mutated non-small cell lung cancer patients
Antonio Rossi
Potential role of antiestrogens in treating ovarian cancer
Sumegha Mitra, Anirban K. Mitra
Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
Federico Longo, Pablo Reguera, Alfredo Carrato
Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable?
Hakan Köksal, Sébastien Wälchli
Neoadjuvant versus definitive chemoradiation for locally advanced esophageal squamous cell carcinoma
Carl M. Post, Matthias F. Haefner, Chi Lin, Charles B. Simone II, Vivek Verma
Epigenetic mutations and cancer therapy Effectiven(EZH2)
Cristina Segovia, Jesús M. Paramio, Mónica Martínez-Fernández
The role of in-bore magnetic resonance imaging guided biopsy for the detection of clinically significant prostate cancer
Sunao Shoji
Editorial on combination treatment beyond sorafenib alone for hepatocellular carcinoma with portal vein tumor thrombosis
Sun Hyun Bae, Hee Chul Park
Ceritinib and cabozantinib: new tyrosine kinase inhibitors improve treatment options for non-small cell lung cancer patients
Santiago Viteri, Rafael Rosell
How upfront can we be about upfront therapy for brain metastases in patients with activating epidermal growth factor receptor mutation?
Dae Ho Lee